Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects

Trial Profile

Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Itraconazole (Primary) ; LY 3323795 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Jun 2017 Planned End Date changed from 11 Sep 2017 to 1 Oct 2017.
    • 09 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
    • 08 Mar 2017 Planned End Date changed from 6 Jul 2017 to 11 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top